PharmaFab revises manufacturing procedures
Executive Summary
PharmaFab is revising its standard operating procedures for manufacturing following FDA 1warning letter. The June 15 letter followed inspection of PharmaFab's manufacturing facility in Grand Prairie, Tex. from Jan. 5 through Jan. 14. FDA's citations include inadequate procedures for handling reprocessed batches, conducting stability tests and preventing of objectionable microorganisms in drug products not required to be sterile. FDA noted that PharmaFab's responses were sufficient for five of the eight issues listed in the warning letter...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.